Certican® (everolimus) in de novo heart transplantation

被引：0
|
作者：
Valantine, H
Zuckermann, A
Hummel, M
Lehmkuhl, H
Epailly, E
Fiane, A
Manito, N
Perrone, S
机构：
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2005年 / 24卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S211 / S211
页数：1
相关论文
共 50 条
  • [31] IMPACT OF EVEROLIMUS ON PERICARDIAL AND PLEURAL EFFUSIONS IN DE NOVO HEART TRANSPLANT RECIPIENTS
    Barten, M.
    Zuckermann, A.
    Arizon, J. M.
    Dong, G.
    Eisen, H.
    Kobashigawa, J.
    Lehmkuhl, H. B.
    Pellegrini, C.
    Ross, H.
    TRANSPLANT INTERNATIONAL, 2010, 23 : 8 - 8
  • [32] Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities
    Pascual, Julio
    Diekmann, Fritz
    Fernandez-Rivera, Constantino
    Gomez-Marques, Gonzalo
    Gutierrez-Dalmau, Alex
    Jose Perez-Saez, Maria
    Sancho-Calabuig, Asuncion
    Oppenheimer, Federico
    NEFROLOGIA, 2017, 37 (03): : 253 - 266
  • [33] Everolimus in De novo cardiac transplantation: Pharmacokinetics, therapeutic range, and influence on cyclosporine exposure
    Kovarik, JM
    Eisen, H
    Dorent, R
    Mancini, D
    Vigano, M
    Rouilly, M
    Hsu, CH
    Rordorf, C
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (10): : 1117 - 1125
  • [34] Everolimus Is Associated With a Reduced Incidence of Herpes Zoster Following De Novo Kidney Transplantation
    Goto, N.
    Nishihira, M.
    Hidaka, Y.
    Yamamoto, T.
    Tsujita, M.
    Hiramitsu, T.
    Narumi, S.
    Kabayashi, T.
    Watarai, Y.
    TRANSPLANTATION, 2014, 98 : 623 - 624
  • [35] MTOR polymorphisms and de novo diabetes mellitus in liver transplantation patients treated with everolimus
    Hagemann, A.
    Husen, P.
    Straub, K.
    Willuweit, K.
    Wedemeyer, H.
    Bachmann, H. S.
    Herzer, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (SUPPL 1) : S25 - S25
  • [36] Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation
    Kobashigawa, J.
    Ross, H.
    Bara, C.
    Delgado, J. F.
    Dengler, T.
    Lehmkuhl, H. B.
    Wang, S. -S.
    Dong, G.
    Witte, S.
    Junge, G.
    Potena, L.
    TRANSPLANT INFECTIOUS DISEASE, 2013, 15 (02) : 150 - 162
  • [37] Clinical experience with Certican® (everolimus) in maintenance heart transplant patients at the Medical University of Vienna
    Zuckermann, A
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (04): : S206 - S209
  • [38] The promise of C2, simulect, and certican in heart transplantation
    Delgado, DH
    Ross, HJ
    TRANSPLANTATION PROCEEDINGS, 2004, 36 (02) : 504S - 508S
  • [39] Everolimus Immunosuppression in De Novo Heart Transplant Recipients: Clinical and Intravascular Ultrasound Study
    Choi, H.
    Hong, J.
    Kim, M.
    Lee, S.
    Kim, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S280 - S280
  • [40] Psychiatric Morbidity in De Novo Heart Transplant Recipients on Everolimus-Based Immunosuppression
    Buerker, B. S.
    Malt, U. F.
    Gude, E.
    Gullestad, L.
    Relbo, A.
    Grov, I.
    Andreassen, A. K.
    Fiane, A. E.
    Haraldsen, I. R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S288 - S289
12345